Hoppervasquez5674

The absolute count of Treg cells was an independent prognostic factor of the risk stratification.

At the beginning of diagnosis, the reduction of the absolute count of Treg cells in peripheral blood of DLBCL patients show a poor prognosis.

At the beginning of diagnosis, the reduction of the absolute count of Treg cells in peripheral blood of DLBCL patients show a poor prognosis.

To investigate the clinical features and prognostic factors of patients with extranodal NK/T cell lymphoma (ENKTL).

The clinical data of patients with ENKTL from November 2009 to November 2019 was collected and retrospectively analyzed to clarify the clinical features of ENKTL, and evaluate the factors that affected survival and prognosis.

Forty-seven patients with ENKTL were collected, median age was 40 (12-82) years old, and more common in males than females, at the ratio of 1.47∶ 1. The median follow-up was 28 (1-112) months, and 5-year overall survival (OS) rate was 49.3%. The 5-year OS rates of the subjects with ECOG performance stage 0-1 and ≥2 were 51.6% and 0 (P=0.001), respectively. The 5-year OS rates of International Prognostic Index (IPI) score 0-1 and ≥2 were 60.0% and 40.6% (P=0.027), respectively. The 5-year OS rates of Ann Arbor staging Ⅰ/Ⅱ and stage Ⅲ/Ⅳ were 61.3% and 31.7% (P=0.005), respectively. The 5-year OS rates of the patients with presentation of B symptoms and without presentatatients with ENKTL.AbstractObjective To investigate the effeciency of autologous hematopoietic stem cell transplantation (auto.HSCT) combined with rituximab(R) to treat CD20+ B non.Hodgkin lymphoma(B.NHL).

From January 2005 to December 2013, 83 patients with refractory/recurrent CD20

B.NHL who were treated with auto.HSCT in our department were enrolled. The patients were divided into 2 groups 57 patients in Rituximab group, and 26 patients in control group(without Rituximab). All the patients received chemotherapy and auto.HSCT. For the patients in treatment group, Tituximab was used before transplantation of the stem cells, and for some patients Rituximab was used after transplantation. For the patients in control group, the induction, enhancement and transplantation were the same as those in treatment group. The clinical efficiency of the patients in treatment group according to the time and frequency of R was analyzed in subgroups and compared with the control group. The deadline of follow.up was April 30 2014.

All the actory/recurrent CD20

B.NHL, the combination of R and inducing chemotheraphy, purify in body before transplantation, as well as continue with R after auto.HSCT could obviously improve the OS and EFS of patients. For the patients who with R before and after transplantation, their EFS is better than the patients with R before transplantation only.

For the patients with refractory/recurrent CD20+ B.NHL, the combination of R and inducing chemotheraphy, purify in body before transplantation, as well as continue with R after auto.HSCT could obviously improve the OS and EFS of patients. For the patients who with R before and after transplantation, their EFS is better than the patients with R before transplantation only.

To observe the effects of tripterine on adhesion molecules and cell biological characteristics in mice with acute promyelocytic leukemia (APL) tumor.

Eighteen SCID beige mice were caudal vein injected with NB4 cell lines (5×10

/only) to construct a human APL tumor-bearing model, then the mice were divided into tumor-bearing model group, arsenic trioxide group and tripterine group randomly, and another 6 mice which didn't construct model were set up as control group; after 3 weeks, the control group and the tumor-bearing model were intraperitoneally injected with normal saline as compared, arsenic trioxide was intraperitoneally injected according to 100 μg/kg, and tripterine was intraperitoneally injected according to 3 mg/kg. Four groups were all injected for 3 weeks. The biological characteristics of NB4 cells and the expression of adhesion molecules in venous blood of mice after treatment were observed.

The neutrophil decrased and promyelocytes, NB4 cells, B lymphocytes and white blood cells increaseCAM-1 and sICAM-1 proteins in APL tumor-bearing mice and reduce the adhesion of tumor cells, but also block tumor cells at G

-M and S phases, thereby exerting therapeutic effect on APL.

Tripterine may not only inhibit the expression of sVCAM-1 and sICAM-1 proteins in APL tumor-bearing mice and reduce the adhesion of tumor cells, but also block tumor cells at G2-M and S phases, thereby exerting therapeutic effect on APL.

To explore the effects of costunolide on the proliferation and apoptosis of human chronic myeloid leukemia drug resisitant cell line K562/ADR and its mechanism.

The proliferation of the cells was assessed by CCK-8 assay, while flow cytometry was used to detect the apoptosis of the cells. Sunitinib PDGFR inhibitor The related-proteins were detected by using Western blot.

The proliferation of K526/ADR cells was significantly inhibited by costunolide in a dose-dependent manner (r=0.9886) after treated by 0.01, 0.1, 0.25, 0.5, 1, 2.5, 5, 10, 25, 50 and 100 μmol/L costunolide for 72 h, and IC

value of costunolide on K562/ADR cells was about (10.86±0.99) μmol/L (P<0.05). The apoptosis of K562/ADR cells could be induced by costunolide (10 and 15 μmol/L) significantly, the rate of apoptosis was 14.80%±3.27%, 33.2%±5.03%, respectively, which in comparison with a significantly difference as compared with the control group (4.30%±0.62%) (P<0.05). Western blot showed that costunolide could down-regulated the expression of p-AKT, p-PI3K, BCL-2, and up-regulated the expression of cleaved-caspase-3, cleaved-PARP significantly.

Costunolide could inhibit the proliferation and apoptosis of K562/ADR cells through regulation of PI3K/AKT pathway.

Costunolide could inhibit the proliferation and apoptosis of K562/ADR cells through regulation of PI3K/AKT pathway.

To explore the effects and mechanisms of PKC412 inhibitor on proliferation and apoptosis of HL-60 cell line.

CCK-8 assay was used to detect the effect of PKC412 on the proliferation of HL-60 cells at different concentrations; Wright-Giemsa staining was used to estimated the effect of PKC412 on the apoptosis of HL-60 cells; the mRNA expression of BCL-2 and P53 genes was detected by qRT-PCR, the expression of BCL-2 and P53 proteins was detected by Western blot. HL-60 cells were injected into mouse caudal vein to construct acute myeloid leukemia model, PKC412 was administered to tail vein for 31.25 nmol/kg, normal saline was injected into the same site of the mice as control group, and the inhibitory effect of PKC412 on HL-60 cells in mice was observed. ELISA assay was used to detect the effect of PKC412 on the inflammatory factors of TNF-α and TGF-β in tumor mice.

PKC412 could inhibit the proliferation of HL-60 cell, which was in a dose dependent manner(r=0.9973) (IC50 was 0.31 μmol/L), and induce apoptosis of HL-60 cells.